| |
|
|
|
Trillium Therapeutics Inc.
|
|
7.35 +0.20 (+2.80%) |
10/23/2017 3:59pm |
|
Open: |
7.05 |
Pre close: |
7.15 |
Target:
|
8.64 
|
|
High: |
7.40 |
Low: |
7.05 |
Resistance:
|
7.40
8.64
|
|
Volume: |
87,700 |
Market Cap: |
79.34M |
Support:
|
5.76
4.75
|
|
|
|
|
Technical Analysis |
|
Moving Averages |
MA(5):
|
6.93
|
MACD |
MACD(12,26):
|
0.55 |
|
MA(20): |
5.78 |
Signal(12,26,9): |
0.38 |
|
MA(100): |
4.89 |
Stochastic Oscillator |
%K(14,3):
|
90.82 |
|
MA(250): |
5.88  |
%D(3): |
85.33 |
|
Average Volume(K) |
3-Month: |
6508
|
52-Week |
High:
|
15.50 |
|
10-Days: |
14156 |
Low: |
4.15 |
|
RSI |
RSI(14):
|
78.33 |
Change(%): |
-47.7 |
|
Financials, Statistics and Valuation |
|
EPS |
-4.080 |
Return on Equity (ttm) |
-54.1 |
Shares Out. (M) |
10.00 |
|
EPS Est. Current Year |
-4.150 |
Return on Assets (ttm) |
-29.6 |
Shares Float (M) |
8.03 |
|
EPS Est. Next Year |
-2.990 |
PEG Ratio |
0.00 |
% Held by Insiders |
3.95 |
|
EPS Est. Next Quarter |
-0.990 |
Qtrly Rev. Growth |
0.0 |
% Held by Institutions |
56.54 |
|
Forward EPS |
-3.029 |
Gross Profit (p.s.) |
0.000 |
Shares Short (K) |
70 |
|
Book Value (p.s.) |
1.740 |
EBITDA (p.s.) |
-2.862 |
P/E |
-1.80 |
|
Sales Per Share |
0.000 |
Qtrly Earnings Growth |
0.00 |
P/BV |
4.22 |
|
Profit Margin |
0.00 |
Operating Cash Flow
(M) |
-21.55 |
P/S |
0.00 |
|
Operating Margin |
0.00 |
Levered Free Cash Flow
(M) |
-8.84 |
P/CF |
-3.41 |
|
|
|
|
|
|
|
